Aim of the study: The aim of the study was to analyze three single nucleotide polymorphisms – rs1520220, rs2946834, rs6219 – of the IGF-1 gene in the context of breast mammographic density.

Material and methods: The research material included 202 samples of the peripheral blood of women with increased mammographic breast density and 238 samples of the epithelium from the oral mucosa of women without diagnosed pathological changes of the breast and with no family history of breast and/or ovarian cancer. The real-time polymerase chain reaction method was applied for analysis of polymorphisms.

Results: rs1520220 polymorphism was associated with increased mammographic density of the breasts. The presence of the CC genotype in the IGF-1 gene increased the risk of developing higher breast density visible in mammography by 2.43-fold. CC homozygotes (rs1520220) correlated with higher Breast Imaging-Reporting and Data System scale (3 vs. 4 and 5) (OR = 5.6; 95% CI: 1.82–16.3, p = 0.001). In the present study no relationship was detected between rs6219 and rs2946834 polymorphism and mammographic breast density.

Conclusions: The results suggest that the rs1520220 polymorphism of the IGF-1 gene plays an important role in the occurrence of increased mammographic breast density.

Key words: mammographic breast density, IGF, polymorphism, breast cancer.

Introduction

The amount of radiographically dense breast tissue shown on a mammogram varies from woman to woman due to differences in the composition of the breast tissue and is referred to as mammographic density. Mammographic density is a strong risk factor for breast cancer and the risk of breast cancer is 4–5 times higher in women with a higher density in more than 75% of the breast area than in women with little or no breast density. Dense tissue in more than 50% of the breast surface can explain about one-third of breast cancers [1–4].

Our limited understanding of the biology of mammographic density makes the selection of candidate genes difficult. Moreover, mammographic density is a dynamic feature, decreasing with age and menopause, and even changing temporarily during the menstrual cycle. Higher density is observed in premenopausal women, nulliparous with a low body mass index (BMI) or using combination postmenopausal hormone, and lower in postmenopausal women, multiparous, with a high BMI or treated with tamoxifen [5]. Because of these hormonal influences, most candidate gene research has focused on evaluating the pathways that regulate the synthesis and metabolism of steroid hormones, hormone receptors, and proliferative pathways, including the insulin-like growth factor pathway. However, some studies have focused on genes that were previously noted as strongly (BRCA1/BRCA2) or hypothetically (XPD, XRCC3 and ERBB2) associated with breast cancer risk [5]. Literature data indicate that the most common genes for predisposition to breast carcinoma are: ATM, BARD1, BRCA1/2, CDH1, CHEK2, Nf1, PALB2, PTEN, RAD51C, RAD51D and TP53 [6]. A recent study confirmed the risk of breast cancer in women with neurofibroma type 1 (NF-1) [7]. As for the Nf1 gene, the so-called first hit mutation guaranteed that further carcinogenesis is inherited germlinically in patients with NF-1 [8, 9].

So far, many studies have been carried out on genetic factors that may affect breast density [10–14]. Yet, it has been suggested that some elements of the insulin-like growth factor 1 (IGF-1) pathway are associated with breast density and IGF levels [11, 12]. Scientific experiments show the relationship between single nucleotide polymorphisms (SNPs) in the IGF-1 and IGFBP-3 gene region with breast density [15–26]. It is also known that SNPs in insulin receptor substrate 1 (IRS1), insulin-like growth factor receptor 1 (IGF1R) and phosphoinositide-3-kinase, catalytic, β-polypeptide (PI3KCB) genes may affect breast morphology and carcinogenesis [20].

An association was observed between the rs1520220 and rs6220 polymorphisms of the IGF-1 gene and rs1801278 of the IRS gene and high breast density, while the rs361072 polymorphism of the PI3KCB gene was associated with low breast density [27]. Four SNPs of the IGFBP-3 gene (rs2132572, rs1520220, rs2946834 and rs6219) in Polish women.

Beata Smolarz1, Ireneusz Polač2, Hanna Romanowicz1

1Laboratory of Cancer Genetics, Department of Pathology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
2Division of Reproductive Medicine, Gameta Hospital – Lodz, Rzgow, Poland

Contemp Oncol (Pozn) 2021; 25 (3): 191–197
DOI: https://doi.org/10.5114/wo.2021.109727

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).
License (http://creativecommons.org/licenses/by-nc-sa/4.0/)
rs2854744, rs2471551 and rs3110697) were related to the levels of IGF-1 and IGFBP-3 [27]. The association of the following SNPs of the IGF-1 gene with increasing IGF-1 levels was demonstrated: rs9989002, rs2033178, rs7136446, rs978458 and rs6220. These polymorphisms were slightly associated with breast density in premenopausal women. A much stronger correlation was found between polymorphisms and mammographic breast density in postmenopausal women. The most statistically significant results were obtained for the rs6220 polymorphism and the IGF-1 level. Research suggests a link between IGF-1 genetic variants and fluctuating protein levels. However, their relationship with breast density has not been fully confirmed [27].

Research indicates that the IGF pathway may influence the risk of breast cancer by affecting the morphogenesis of breast tissue [28]. The studies of Verheus et al. showed that the rs9989002, rs2033178, rs7136446, rs978458, and rs6219 polymorphisms were significantly associated with an increase in IGF-I levels, but they did not correlate with breast density in the studied women [28].

IGF-1 gene SNPs may affect the level of IGF1 protein in tissues [29, 30]. It has been shown that the rs1520220 or rs6220 polymorphisms in the IGF-1 gene region correlate with a high level of the IGF1 protein encoded by this gene, and thus with a high risk of breast cancer [29].

The aims of the study were:
- to analyze the SNPs rs1520220, rs2946834, rs6219 of the IGF-1 gene in a group of women diagnosed with increased mammographic breast density and in a control group,
- to correlate the obtained results with clinical and pathological data,
- to determine the significance of the obtained results in the context of increased breast mammographic density.

### Material and methods

#### Patients

The research material included 202 samples of peripheral blood of women with increased mammographic density and 238 preparations of the epithelium of the oral mucosa in women without diagnosed pathological changes of the breast and no family history of breast and/or ovarian cancer. The severity of mammographic breast density in women was classified according to the six-point Breast Imaging-Reporting and Data System (BIRADS) scale [31, 32]. The clinical and pathological characteristics of the studied group of women are presented in Table 1. The Polish Mother’s Memorial Hospital Research Institute Ethical Committee approved the design of the study (No. 10/2012).

#### Genomic DNA isolation

Genomic DNA extraction was performed from peripheral blood using the commercially available EXTRACTME DNA Blood Kit (Blirt, Poland) according to the manufacturer’s instructions. DNA was extracted from oral mucosa swabs, using a commercially available Extractme DNA Swab & Semen Kit (Blirt, Poland), according to the manufacturer’s instructions.

#### Single nucleotide polymorphism genotyping

Three SNPs in the IGF-1 gene were selected according to the National Center for Biotechnology Information SNPs database: rs6219, rs1520220 and rs2946834. All SNPs were believed to have minor allele frequency (MAF) > 5%. Genotyping of 3 SNPs was performed with the allelic discrimination method using TaqMan probes labeled with VIC and FAM according to the manufacturer’s instructions (C__11495137_10, C__2801118_10, C__2861121_10).

Polymerase chain reaction (PCR) amplifications were conducted in a total volume of 10 µL and consisted of 5 µL

---

**Table 1. Clinical-pathological characteristics of patients**

<table>
<thead>
<tr>
<th></th>
<th>Increased mammographic breast density (%)</th>
<th>Control (%)</th>
<th>p test χ² breast density vs. control</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of samples</strong></td>
<td>202</td>
<td>238</td>
<td></td>
</tr>
<tr>
<td><strong>Age group</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35–44</td>
<td>0 (0)</td>
<td>3 (1.26)</td>
<td>0.003</td>
</tr>
<tr>
<td>45–54</td>
<td>92 (45.5)</td>
<td>78 (32.8)</td>
<td></td>
</tr>
<tr>
<td>55–64</td>
<td>95 (47.1)</td>
<td>119 (50.0)</td>
<td></td>
</tr>
<tr>
<td>65+</td>
<td>15 (7.4)</td>
<td>38 (15.9)</td>
<td></td>
</tr>
<tr>
<td><strong>BMI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 24.9</td>
<td>137 (67.8)</td>
<td>102 (42.8)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>25–29.9</td>
<td>52 (25.7)</td>
<td>67 (28.1)</td>
<td></td>
</tr>
<tr>
<td>&gt; 30</td>
<td>13 (6.5)</td>
<td>69 (29.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Age of menarche</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 14</td>
<td>97 (48.0)</td>
<td>118 (49.6)</td>
<td>0.56</td>
</tr>
<tr>
<td>12.13</td>
<td>80 (39.6)</td>
<td>98 (41.2)</td>
<td></td>
</tr>
<tr>
<td>&lt; 12</td>
<td>25 (12.4)</td>
<td>22 (9.2)</td>
<td></td>
</tr>
<tr>
<td><strong>Number of pregnancies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1</td>
<td>101 (50.0)</td>
<td>101 (42.4)</td>
<td>0.24</td>
</tr>
<tr>
<td>2–3</td>
<td>83 (41.1)</td>
<td>116 (48.7)</td>
<td></td>
</tr>
<tr>
<td>≥ 4</td>
<td>18 (8.9)</td>
<td>21 (8.9)</td>
<td></td>
</tr>
<tr>
<td><strong>Hormonal treatment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>56 (27.7)</td>
<td>71 (29.8)</td>
<td>0.62</td>
</tr>
<tr>
<td>No</td>
<td>146 (72.3)</td>
<td>167 (70.2)</td>
<td></td>
</tr>
<tr>
<td><strong>BIRADS scale</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Category 3</td>
<td>26 (12.9)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Category 4</td>
<td>167 (82.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Category 5</td>
<td>9 (4.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Menopausal status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premenopausal</td>
<td>25 (12.4)</td>
<td>15 (6.3)</td>
<td>0.07</td>
</tr>
<tr>
<td>Peri-menopausal</td>
<td>45 (22.3)</td>
<td>51 (21.4)</td>
<td></td>
</tr>
<tr>
<td>Post-menopausal</td>
<td>132 (65.3)</td>
<td>172 (72.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Cigarettes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>78 (38.6)</td>
<td>84 (35.3)</td>
<td>0.47</td>
</tr>
<tr>
<td>No</td>
<td>124 (61.4)</td>
<td>154 (64.7)</td>
<td></td>
</tr>
</tbody>
</table>

BMI – body mass index, BIRADS – Breast Imaging-Reporting and Data System
Table 2. Associations between IGF-1 single nucleotide polymorphisms and mammographic breast density

<table>
<thead>
<tr>
<th>SNP genotype</th>
<th>Cases (%), controls (%)</th>
<th>OR (95% CI)b</th>
<th>p</th>
<th>OR (95% CI)b</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs6219</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>52 (25.7), 62 (26.0)</td>
<td>1.00 (reference)</td>
<td>0.98</td>
<td>1.00 (reference)</td>
<td>0.92</td>
</tr>
<tr>
<td>CT</td>
<td>96 (47.5), 114 (47.9)</td>
<td>1.00 (0.63–1.58)</td>
<td>0.88</td>
<td>1.03 (0.58–1.57)</td>
<td>0.86</td>
</tr>
<tr>
<td>TT</td>
<td>54 (26.8), 62 (26.3)</td>
<td>1.04 (0.61–1.74)</td>
<td>1.07 (0.69–1.82)</td>
<td>0.12</td>
<td></td>
</tr>
<tr>
<td>p trendd</td>
<td>0.89</td>
<td>0.94</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT or TT vs. CC</td>
<td>150 (74.2), 176 (73.9)</td>
<td>0.98 (0.64–1.50)</td>
<td>0.78</td>
<td>0.98 (0.63–1.50)</td>
<td>0.94</td>
</tr>
<tr>
<td>CT or CC vs. TT</td>
<td>148 (73.2), 176 (73.9)</td>
<td>1.06 (0.25–9.17)</td>
<td>1.04 (2.24–9.12)</td>
<td>0.71</td>
<td></td>
</tr>
<tr>
<td>rs1520220</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>30 (14.8), 41 (17.2)</td>
<td>1.00 (reference)</td>
<td>1.00</td>
<td>1.00 (reference)</td>
<td>0.35</td>
</tr>
<tr>
<td>GC</td>
<td>68 (33.7), 119 (50.0)</td>
<td>0.78 (0.44–1.37)</td>
<td>0.62 (0.38–1.37)</td>
<td>0.024</td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>104 (51.5), 78 (32.8)</td>
<td>2.41 (1.04–4.19)</td>
<td>0.38</td>
<td>2.43 (1.11–4.52)</td>
<td>0.07</td>
</tr>
<tr>
<td>p trendd</td>
<td>0.002</td>
<td>0.033</td>
<td></td>
<td></td>
<td>0.007</td>
</tr>
<tr>
<td>GC or CC vs. GGd</td>
<td>172 (85.1), 197 (82.8)</td>
<td>2.65 (0.73–9.38)</td>
<td>0.012</td>
<td>2.25 (0.73–11.34)</td>
<td>0.25</td>
</tr>
<tr>
<td>GC or GG vs. CCd</td>
<td>98 (48.5), 160 (67.2)</td>
<td>1.44 (0.71–2.76)</td>
<td>0.31</td>
<td>1.42 (0.72–2.86)</td>
<td>0.07</td>
</tr>
<tr>
<td>rs2946834</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>69 (34.6), 95 (39.9)</td>
<td>1.00 (reference)</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GA</td>
<td>102 (52.5), 108 (45.4)</td>
<td>102 (34.6), 108 (45.4)</td>
<td>0.21</td>
<td>1.32 (0.86–1.97)</td>
<td>0.48</td>
</tr>
<tr>
<td>AA</td>
<td>31 (30.8), 35 (14.7)</td>
<td>31 (30.8), 35 (14.7)</td>
<td>0.50</td>
<td>1.26 (0.71–2.23)</td>
<td>0.07</td>
</tr>
<tr>
<td>p trendd</td>
<td>0.08</td>
<td>0.08</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GA or AA vs. GGd</td>
<td>132 (65.3), 143 (60.1)</td>
<td>132 (65.3), 143 (60.1)</td>
<td>0.11</td>
<td>2.35 (0.75–4.01)</td>
<td>0.12</td>
</tr>
<tr>
<td>GA or AA vs. AAd</td>
<td>140 (69.3), 203 (85.2)</td>
<td>140 (69.3), 203 (85.2)</td>
<td>0.15</td>
<td>1.75 (0.87–2.12)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

SNP – single nucleotide polymorphisms, a – crude, b – adjusted for age, and smoking status, c – testing additive genetic model (Cochran-Armitage test for trend), d – testing dominant genetic model, e – testing recessive genetic model

Results

The number of patients in age ranges, both in the study and control groups, is summarized in Table 1. All of the studied individuals, patients and controls, were Caucasians. Some additional clinical data of the patients in the studied group are presented in Table 1. Genotype and allele distributions in the IGF-1 gene in 202 MD patients and 238 controls are summarized in Table 2. All genotype and allele frequencies (rs6219, rs1520220, rs2946834) were confirmed as compatible with Hardy-Weinberg equilibrium among the case and controls (all p > 0.05). As a result, only rs1520220 SNP in the IGF-1 gene was significantly related to higher mammographic breast density in this population-based case-control study. The frequency of detected G allele carriage was 31.7% and 42.2% in cases and controls, respectively. C allele carriage was detected in 68.3% of mammographic breast density (MBD) patients and 57.8% of control subjects. The genotype frequency distribution of the rs1520220 SNP was as follows: 17.2% (GG), 50.0% (GC), and 32.8% (CC) in healthy controls and 14.8% (GG), 33.7% (GC), and 51.5% (CC) in patients. Likewise, genotype distribution concerning BMI and using hormonal replacement therapy (HRT) was found to be very similar. IGF-1 gene SNPs in relation to age, BMI, menarche, pregnancy, HRT, menopausal, and smoking status in cases and controls are shown in Table 3. Significant interactions with age, pregnancy, and menopausal status were observed in cases. It should also be emphasized that MBD individuals ≥ 54 years of age had heterozygosity (GC) at the rs1520220 SNP.
(22.3%), while in younger women this genotype was observed in 11.4%. Homozygosity (GG) was observed in 4.4% of patients with > 1 pregnancy and 10.3% of patients with ≤ 1 pregnancy. However, in the case of the GC genotype, we found an inverse relationship (15.3% and 8.4% respectively). The CC genotype was most common in postmenopausal MBD patients (39.2%). In the control group, statistically significant differences in the distribution of genotypes were observed with regard to age, menarche, number of pregnancies, and smoking status (Table 4).

Our findings reinforce the association of IGF-1 (rs1520220) with mammographic breast density. In the study population, a pathogenic link between the rs6219 and rs2946834 variants and MBD was not detected. The genetic association analysis revealed the presence of CC genotype at the IGF-1 gene was at higher risk with an approximately 2.43-fold increase for the development of higher mammographic breast density. Moreover, confirmation of one copy of the risk allele C at this locus (rs1520220) of the IGF-1 gene conferred an estimated increase risk of MBD of almost 2.25-fold in the model adjusted for age and smoking status (OR = 2.25; 95% CI: 0.73–11.34, p\text{dominant} = 0.007). The atypical homozygotes (CC rs1520220) appeared to have a higher BIRADS category (3 vs. 4 and 5) (OR = 5.6; 95% CI: 1.82–16.3, p = 0.001).

### Discussion

In the Introduction we cited a variety of current literature to present compelling evidence that polymorphisms

Table 3. IGF-1 gene rs1520220 polymorphism in relation to demographic and clinical parameters

<table>
<thead>
<tr>
<th>Variable</th>
<th>Genotype n (%)</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GG</td>
<td>GC</td>
</tr>
<tr>
<td>Age</td>
<td>&lt; 54 years</td>
<td>18 (8.9)</td>
</tr>
<tr>
<td></td>
<td>≥ 54 years</td>
<td>12 (5.9)</td>
</tr>
<tr>
<td>BMI</td>
<td>&lt; 24.9</td>
<td>18 (8.9)</td>
</tr>
<tr>
<td></td>
<td>≥ 25.0</td>
<td>12 (5.9)</td>
</tr>
<tr>
<td>Menstruation</td>
<td>&lt; 14</td>
<td>13 (6.4)</td>
</tr>
<tr>
<td></td>
<td>≥ 14</td>
<td>17 (8.4)</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>0–1</td>
<td>21 (10.3)</td>
</tr>
<tr>
<td></td>
<td>&gt; 1</td>
<td>9 (4.4)</td>
</tr>
<tr>
<td>HRT</td>
<td>Yes</td>
<td>13 (6.4)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>17 (8.4)</td>
</tr>
<tr>
<td>Menopausal status</td>
<td>Pre- and peri-</td>
<td>16 (7.9)</td>
</tr>
<tr>
<td></td>
<td>Post-</td>
<td>14 (6.9)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Smokers</td>
<td>15 (7.4)</td>
</tr>
<tr>
<td></td>
<td>Non-smokers</td>
<td>15 (7.4)</td>
</tr>
</tbody>
</table>

Table 4. Associations between clinicopathological characteristics (Breast Imaging-Reporting and Data System) and breast mammographic density

<table>
<thead>
<tr>
<th>Variable</th>
<th>rs1520220 OR (95% CI)*</th>
<th>p</th>
<th>OR (95% CI)*</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIRADS 3 vs. 4 and 5</td>
<td>21 (10.4), 77 (38.1)</td>
<td>5 (2.5), 99 (49.0)</td>
<td>5.4 (1.94–15.0)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

* – crude, † – adjusted for age, and smoking status, BIRADS – Breast Imaging-Reporting and Data System

\[ p = 0.001 \]
of IGF-1 play a considerable role in breast morphology [34–36]. Some genotypes of these polymorphisms have already been studied in breast density, but this area of research remains mostly unexplored [37–44].

In experimental research by Al-Zahrani et al., five IGF-1 gene polymorphisms—rs5742678, rs5742694, rs1520220, rs6220 and rs2946834—showed a statistically significant relationship with the change of IGF-1 level in women, but not in men [45]. The less frequent alleles of these polymorphisms were associated with high IGF-1 levels. The two SNPs rs5742615 and rs1549593 did not correlate with IGF-1 levels in menopausal women, but were associated with high levels of this protein in the age-matched group of men. The rs6214 and rs6219 polymorphisms were not related to IGF-1 levels in either sex [45].

Research has shown that gene polymorphisms in the IGF pathway are related to breast density or IGF-1 levels. Genetic analyses have provided support for the hypothesis that some elements of the IGF pathway may influence the risk of breast cancer and this effect is a result of their influence on the morphogenesis of breast tissues [27].

Genetic variants of IGF gene polymorphisms play a significant role in mammographic breast density development [46–50].

In our study we found a relationship between the rs1520220 polymorphism and the presence of mammographic breast density. The rs1520220 polymorphism is located in intron 3 of the IGF-1 gene [51]. Literature data indicate that rs1520220 affects the level of IGF-1 protein, encoded by this gene in breast tissues [29, 52]. The rs1520220 polymorphism in intron 3 is associated with high IGF-1 levels and hence a high risk of breast cancer [53–55].

A significant relationship of this polymorphism with IGF-1 levels has been demonstrated in a population of women from the United Kingdom [21, 52]. It has been shown that the rs1520220 polymorphism of the IGF-1 gene is associated with high breast density [23, 51]. However, there are reports that in women who are carriers of the rs1520220 polymorphism, the breast density is low [24, 30, 56].

World literature data indicate that in premenopausal women polymorphic variants of the IGF pathway genes such as IGF-1, IGFBP-3, IRS1, and PI3KCB may affect breast density and the level of growth factors. This suggests that components of the IGF system may be involved in the development of breast cancer [55].

In the present study the rs2946834 polymorphism located in the 3’ untranslated region of the IGF-1 gene was analyzed. This is an important region where there are various signal sequences such as sequences of the signal for polyadenylation, usually AAUAAA, sequences affecting the location of mRNA in the cell, sequences affecting the stability of mRNA (e.g. AURE sequences rich in adenine and uracil), and sequences affecting translation and miRNA binding sites [57–61].

The rs2946834 polymorphism is related to the level of IGF-1 in women with breast cancer in the UK population [21]. However, it has not been shown to be directly related to the risk of breast carcinoma developing. Kelemen et al. found that the frequency of the A allele was inversely proportional to the breast density in pre- and postmenopausal women [62].

In the present study, the rs2945834 polymorphism was not associated with mammographic breast density.

Moreover, no relationship between the rs6219 polymorphism and mammographic breast density was observed. A significant relationship with IGF1 levels was found for the rs6219 polymorphism in a population of 2,395 European women (EPIC study) and the rs5742678 polymorphism in a group of 420 women from the United Kingdom [21, 52, 63].

Finally, there are some obvious limitations of our study that need to be mentioned and clarified. The dominant shortcoming of our analysis is the group size: inclusion of 202 cases and 258 controls (440 assays in total) makes an experienced researcher draw final conclusions with care and scepticism. Especially in genetics, our groups may be quantitatively insufficient to make a reliable conclusion.

Having in mind all the above-mentioned findings and being aware of the restrictions of our study, we believe that this research has shed some new light on mammographic breast density.

Conclusions

In conclusion, accumulating evidence indicates that the genetic variation of IGF-1 may contribute to the pathogenesis of mammographic density. The variant genotype of rs1520220 in the IGF-1 gene is strongly associated with the percentage mammographic density in the Polish population.

Acknowledgements

This work was supported by the Institute of Polish Mother’s Memorial Hospital, Lodz, Poland from the Statutory Development Fund. All procedures performed in studies involving human participants are in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All the study participants gave written informed consent. Formal consent was also issued by the Bioethical Committee of the Institute of the Polish Mother’s Memorial Hospital in Lodz (Approval number, 10/2012).

Authors thank Magdalena Brys, Prof., PhD., DSc. and Ewa Forma, PhD (Department of Cytobiochemistry of the University of Lodz, Poland) for help in the scientific experiment.

The authors declare no conflict of interest.

References

7. Karwacki M. Breast cancer risk (un)awareness among women suffering from neurofibromatosis type 1 in Poland. Contemp Oncol 2020; 24: 140-144.

Address for correspondence
Beata Smolarz
Laboratory of Cancer Genetics, Department of Pathology
Polish Mother’s Memorial Hospital Research Institute
Rzgowska 281/289, 93-338 Lodz, Poland
Phone: +48 42 271 12 87
e-mail: smolbea@wp.pl

Submitted: 01.07.2021
Accepted: 13.09.2021